The discovery of homologous recombination led to the knowledge that introducing a double-strand DNA break at a designated site in the genome enhances targeted gene integration.^[@ref1]^ This spurred a plethora of strategies, such as meganucleases, zinc fingers, and TALENS, to selectively introduce double-strand DNA breaks in designated locations at genomes.^[@ref2]^ The most recent technology, [c]{.ul}lustered [r]{.ul}egularly [i]{.ul}nterspaced [s]{.ul}hort [p]{.ul}alindromic [r]{.ul}epeats - [C]{.ul}RISPR-[as]{.ul}sociated protein [9]{.ul} (CRISPR-Cas9), edits genomes based on a guide RNA (gRNA) that targets Cas9, a DNA endonuclease, to specific sites in genomic DNA, thus enabling the addition, elimination, or alteration of DNA sequences at the targeted site in the genome.^[@ref2]^ It has revolutionized our ability to edit the genome of virtually any organism. In this issue of *ACS Central Science*, Pierce and colleagues describe an elegant method to program CRISPR/Cas function by engineering conditional guide RNAs (cgRNAs) whose activity is triggered by the presence of an endogenous RNA trigger.^[@ref3]^

Gene editing based on CRISPR-Cas technology requires two short RNAs, a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA), that together form a trimolecular complex with Cas9 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). The complexed crRNA now guides the endonuclease Cas9 to a specific site in the genome that is complementary to the 5′ end of the crRNA where Cas9 introduces a double strand break ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). Doudna, Charpentier, and co-workers combined the crRNA and tracrRNA to give a single chimeric RNA popularly known now as gRNA ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b).^[@ref4]^ Several groundbreaking studies subsequently emerged showing that CRISPR could edit genomes in vivo and in eukaryotic cells.^[@ref5],[@ref6]^ Studies on gRNAs revealed that Cas9 activity is tolerant of modifications in the crRNA:tracrRNA complementary region.^[@ref7]^ This allows the engineering of gRNAs to facilitate the introduction of auxiliary components that enable the conditional control of gRNA activity via structural changes triggered by small molecules, nucleases, nuclease-recruiting DNA, or photoactivation.^[@ref8]^

![Schematic illustration of the CRISPR/Cas system. Cas9 can be guided by (a) a two-RNA structure formed by trans-activating crRNA (tracrRNA) and CRISPR RNA (crRNA) or by (b) single guide RNA (gRNA) to cleave the specific site in genome. Schematic illustration of the mechanism of Pierce and colleagues' (c) terminator switch cgRNA and (d) toehold switch cgRNA controlling CRISPR/Cas function with endogenous RNA triggers.^[@ref3]^](oc-2019-005508_0001){#fig1}

Here, Pierce and colleagues develop an endogenous RNA-triggered conditional guide RNA (cgRNA) that either turns on or turns off gene expression mediated by Cas9 function. In this system, Pierce uses catalytically dead Cas9 (dCas9) that blocks transcription of the DNA at the binding site.^[@ref9]^ Pierce's team first construct a cgRNA that has a site (blue) containing an extended loop that acts as a binding site for an RNA trigger ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}c). In the absence of the RNA trigger, the cgRNA is capable of complexing dCas9 and guiding it to the target gene where it represses transcription. On the contrary, a complementary RNA trigger (blue) will hybridize with this loop region in the cgRNA resulting in an overall structure that cannot complex with dCas9. This results in the target gene being efficiently transcribed. The performance of the cgRNA is evaluated in *Escherichia coli* that express dCas9, which is targeted to a reporter gene encoding a fluorescent protein. The presence of the cognate RNA trigger enhances protein expression by ∼3--6 fold. The authors then modified the loop length and the number of loops on the cgRNA to further optimize the change in gene expression levels and improve it to ∼18-fold higher expression. This was made possible by a cgRNA design that can enhance dCas9 activity such that gene expression was more effectively shut off. In a final example, Pierce and colleagues demonstrate the reverse logic, where, in the absence of the RNA trigger, the cgRNA is incapable of guiding dCas9 to its target site, which leads to high expression of a target gene. However, in the presence of an RNA trigger, the cgRNA the targeting sequence on the cgRNA is now unmasked, and dCas9 localizes to the target gene, preventing its transcription ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}d).

Although there is a previous description of cgRNAs responsive to an RNA trigger by Siu et al, the RNA trigger turns off target gene expression.^[@ref10]^ In the present study, the presence of an RNA trigger enhances gene expression and can also be engineered to shut off gene expression. Further, the strategy described herein is broadly applicable and demonstrated in both bacteria as well as mammalian cells.

While the ability to control dCas9 function in response to endogenous RNA triggers is an extraordinary addition to the CRISPR toolbox, a few outstanding challenges remain. The fold change in gene expression in mammalian cells is much lower than that achieved in bacteria, only ∼2--5 fold change. This is likely due to potentially higher crosstalk of the cgRNA with other cellular RNA molecules. New cgRNA designs that show lower crosstalk with other RNA sequences would be required for greater effectiveness in eukaryotic systems as well as to toggle the expression of multiple genes in concert. Although biomedical applications seem a little far-fetched at present, the capacity to achieve tissue-specific silencing conditionally would prove particularly powerful to study the role of noncoding RNAs or RNA modifications in organism development.
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